Last updated on December 2019

Radium-223 and Radiotherapy in Hormone-Na ve Men With Oligometastatic Prostate Cancer to Bone

Brief description of study

This is a phase IIa, open label, single arm, and prospective study of hormone therapy-nave men with oligometastatic prostate cancer to the bone. The study will test if treating the primary tumor sites and 5 or fewer sites of bone-only metastasis with external beam radiation with concomitant systemic Radium-223 will reduce the utilization of androgen deprivation therapy, improve QOL and improve OS over a the comparator cohort of SWOG intermittent ADT historic cohort.

Clinical Study Identifier: NCT03304418

Find a site near you

Start Over

Huntsman Cancer Institute

Salt Lake City, UT United States
  Connect »